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This Research Topic entitled “History of Chemoattractant Research” collects a series of personal
stories by numerous experts in the field of chemoattractant research. The individual contributions
portray some key discoveries that helped to transform cell migration research into a global playing
field within immunology (and beyond). Early progress had a profound effect on both academia and
industry. Today, numerous academic laboratories are fully engaged in compiling a detailed roadmap
describing the highly complex network of immune and tissue cells that respond to chemoattractants.
Industrial research, on the other hand, centers on drugs that interfere with immune cell traffic in
inflammatory diseases and cancer.
By definition, chemoattractants include early (“classical”) chemoattractants of variable chemical
composition and the large family of chemokines (chemotactic cytokines) that greatly outnumber the
former compounds. As inferred from their name, all chemoattractants share the ability to induce cell
migration (chemotaxis) via binding to a single class of G-protein-coupled receptors on target cells.
Chemoattractant research was originally viewed as a specialty subject within cell biology. However,
due to the increasing number of chemoattractants being discovered and their effect on every type
of immune cells distributed throughout our body, it became quickly clear that chemoattractants
constitute essential regulators of all aspects in immunity. Defects in the chemoattractant system are
frequently associated with immunodeficiencies or autoimmunity/chronic diseases. We now know
that the complexity of the chemokine and classical chemoattractant system perfectly mirrors the
multitude of immune cells distinguished by lineage relationship, function, and tissue location.
In fact, chemokine receptor profiling turned out to be highly useful for defining immune cell
subsets as exemplified by the numerous T-helper subsets that we know today. Indeed, such work
has led to a fundamental paradigm linking the functional specialization of distinct immune cells
with their migratory behavior. No doubt, the principal and unifying function of chemoattractants
is their ability to induce directional cell migration, involving processes as complex as immune
cell transendothelial migration as well as chemokine gradient-controlled immune cell migration
within tissues. In addition, some chemokines are able to costimulate T-cell differentiation, promote
immune cell survival, or act as antimicrobial peptides in peripheral epithelial tissues. A few
constitutive chemokines are essential for organ development during embryogenesis and some of
these even control tumor cell relocation to secondary sites. Their importance is further emphasized
by the realization that viruses have hijacked host genes encoding chemokines and their receptors
in order to interfere with antiviral immunity or have evolved to use certain chemokine receptors as
entry coreceptors.
The following series of “short stories” provide personal accounts on key discoveries. The
individual molecular discoveries enabled numerous research laboratories worldwide to unravel
their significance in steady-state or pathological immune processes. Although groundbreaking
in their own right, it is worth emphasizing that rapid progress in chemoattractant research was
only made possible by many other laboratories whose work attached “meaning” to these early
findings. The authors of this miniseries are discussing their findings in the context of time, place,
and subsequent progress enabled by their discoveries. It is hoped that a wide readership will
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find these accounts entertaining as well as educational although
those who wish to gain a more detailed knowledge are referred
to the many outstanding reviews on chemokines and other
chemoattractants.
The field of chemokines really started in 1987 with the cloning
of the human gene encoding CXCL8, which occurred in paral-
lel in the laboratories of five independent international groups.
Two stories, one by Marco Baggiolini (1) and the other by Teizo
Yoshimura (2), summarize this groundbreaking discovery and
give a vivid account about the friendly race that ensued from the
realization that activated monocytes secreted neutrophil-specific
chemoattractant activity to the molecular discovery of CXCL8.
Unfortunately, and probably due to the enthusiasm shared by the
research community at that time, it was decided to call CXCL8 an
interleukin (IL-8), which turned out to be a misleading denom-
ination. The three-dimensional structure of CXCL8 is a hall-
mark of all members of the chemokine superfamily and indicated
that, in fact, chemokine-like proteins have been identified several
years before CXCL8. These include IP10 (CXCL10) (3), LD78
(CCL3) (4), and TCA3 (5), the mouse ortholog of human I-309
(CCL1) (6). However, their chemoattractant activity remained
obscure until well after the discovery of CXCL8. Also, platelet
factor 4 (CXCL4) (7–9), the first peptide featuring a prototypi-
cal chemokine fold, was actually never shown to be a chemoat-
tractant. The identification of CXCL8 immediately initiated a
highly competitive search for its receptor(s) and the receptors
for the well-described classical chemoattractant agonists, includ-
ing the formylated bacterial peptide fMLP and the complement
protein C5a. Norma and Craig Gerard summarize these early
events from their own, personal perspective (10). By the early
1990s, the new field of chemokines took off in unprecedented
speed, and it became quickly clear that the newly discovered
chemokines not only targeted neutrophils but alsomonocytes and
many other innate cells and even T and B cells. Tim Williams
tells the exciting story about the discovery of eotaxin (CCL11)
and its involvement in eosinophil recruitment during allergic
diseases (11). Chemokines are implicated not only in infections
and inflammatory diseases but also in homeostatic processes. The
first such chemokine is SDF-1 (CXCL12), and Takashi Nagasawa
tells his story about the importance of SDF-1 in embryogenesis,
hematopoiesis, and even HIV infection (12). Unlike SDF-1, most
homeostatic chemokines do not display a lethal phenotype in
gene-deficient mice yet play an essential role in the traffic control
of immune cells. Early work with orphan chemokine receptors in
mice provided a first indication of the importance of chemokine
receptors, notably BLR1 (CXCR5) (13) and BLR2 (CCR7) (14),
in controlling cellular interactions within secondary lymphoid
tissues (lymph nodes and spleen). I tell the story about how we at
the Theodor-Kocher Institute and Martin Lipp’s group in Berlin
identified CXCR5 as the specific marker for the novel T-helper
cell subset termed follicular B helper T (TFH) cells (15). Not
all chemokine receptors are capable of mediating cell migration
responses, and these “non-signaling” receptors are now collec-
tively called atypical chemokine receptors (ACKR). Three of these,
ACKR1, ACKR2, and ACKR3, with unique functional features
are subject of extensive investigations. ACKR3, previously known
as RDC1 or CXCR7, binds CXCL12 with higher affinity than its
primary receptor CXCR4 and, in addition, binds also CXCL11,
one of the three CXCR3-specific chemokines (16, 17). ACKR3-
deficient mice die in utero (18), suggesting a vital role in embryo-
genesis similar to what has been reported for CXCR4. Richard
Horuk tells the story aboutACKR1, also known asDARCorDuffy
Antigen on red blood cells (19). It is an entry receptor for the
malaria parasite Plasmodium vivax and, surprisingly, acts as a
transcellular transporter of CXCL8 and many other chemokines
in endothelial cells. The story about ACKR2, also known as D6,
is told by Gerard Graham (20) and highlights yet another facet
in chemokine research, namely the modulation of inflamma-
tory milieus by ACKR2 via binding, uptake, and intracellular
degradation of inflammatory chemokines. Chemokines do not act
like normal cytokines do. In fact, immune cells expressing the
corresponding chemokine receptors need to sense a chemokine
gradient, and Amanda Proudfoot highlights the importance of
glycosaminoglycans present on extracellular matrices in this pro-
cess (21). The story by Paolo Lusso (22) describes how his
groundbreaking discovery led to the immediate fusion of two
seemingly unrelated fields of research, “chemokines” and “HIV
infection,” fostering unprecedented collaborations between many
international laboratories. His discovery of CCL3, CCL4, and
CCL5 that acted as HIV-suppressor factors demonstrated that
certain chemokines and possibly their receptors were involved
in HIV infection. Almost simultaneously, fusin was reported to
be the first HIV coreceptor, and this story is told by Edward
Berger (23). Fusin turned out to be identical with the orphan
chemokine receptor LESTR that we have published previously. In
collaboration with Conrad Bleul, we then “deorphanized” LESTR
by showing that this new chemokine receptor (CXCR4) is specific
for CXCL12. Fernando Arenzana-Seisdedos summarizes these
events and tells the story about CXCL12 and its HIV-suppressor
activity (24). CXCR4 is not the only HIV coreceptor. Indeed,
CCL3, CCL4, and CCL5, the HIV-suppressor factors, previously
discovered by Paulo Lusso do not bind to CXCR4. The story by
Marc Parmentier fills this gap and reveals that several groups
worldwide, including his own, discovered CCR5 as the specific
receptor for CCL3, CCL4, and CCL5 (25). CCR5 is the core-
ceptor primarily involved in person-to-person transmission of
HIV, and individuals lacking CCR5 are largely protected against
HIV. In clear contrast to HIV, many viruses carry genes that
target the chemokine system, encoding either inhibitors that inter-
fere with the function of chemokine receptors present on host
immune cells or chemokine-neutralizing proteins with similari-
ties to chemokine receptors, and Philip Murphy’s story touches
on this important aspect of chemokine research (26). Chemokines
and their receptors play a crucial role not only in viral diseases
but also in all other inflammatory diseases as well as cancer.
It is, therefore, obvious that chemokine receptors were selected
as primary targets in translational research. Detailed structural
data of chemokine receptors are of paramount importance for the
design of small-molecular-weight inhibitors, and Tracy Handel’s
story tells about the difficult journey she undertook to accom-
plish a high-resolution crystal structure of CXCR4 (27). Despite
incredible investments by all major drug companies (as well as
many small start-up businesses), the yield of approved chemokine
receptor-specific drugs is still modest. In fact, the two success
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stories about FDA-approved compounds are not related to the
treatment of inflammatory diseases. The first one by Elna van
der Ryst tells the development of Maraviroc, a CCR5 antagonist
used to treat HIV-infected individuals (28), and the second one
by Erik de Clerk summarizes the discovery of the CXCR4-specific
inhibitor AMD3100 and its use in hematopoietic stem cell
mobilization (29).
Chemokine research goes on unabated although the race of
molecular discoveries as highlighted here has well past its zenith.
All major activities are now focused on understanding what all
these original findings really mean. The field has progressed
along so many different and seemingly unrelated routes that writ-
ing comprehensive reviews that cover all aspects of chemokine
research has become a monumental task. One thing is certain,
however, the last two decades have demonstrated once and for
all that chemoattractant research can no longer be considered a
subspecialty of cell biology.
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